(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu5: Discovery of a new tool compound with activity in the OSS mouse model of addiction

ACS Chemical Neuroscience

Volumn 2, Issue 8, 2011, Pages 471-482

  Lindsley, Craig W ^a,b   Bates, Brittney S ^a   Menon, Usha N ^a   Jadhav, Satyawan B ^a   Kane, Alexander S ^a   Jones, Carrie K ^a,c   Rodriguez, Alice L ^a   Conn, P Jeffrey ^a   Olsen, Christopher M ^a   Winder, Danny G ^a   Emmitte, Kyle A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Addiction; MGlu5; Negative allosteric modulator; Noncompetitive antagonist

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 2 METHYL 7 ARYLQUINOLINE; 3 FLUORO 5 (2 METHYLBENZO[D]THIAZOL 5 YL)BENZONITRILE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; BENZENE DERIVATIVE; BENZOXAZOLE DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; QUINAZOLINONE DERIVATIVE; QUINOXALINE; UNCLASSIFIED DRUG;

ADDICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MALE; METABOLIC STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSATION SEEKING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84971012261     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn100099n     Document Type: Article

References (72)

1. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38, 1431-1476.
2. Conn, P. J., and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237.
3. Ritzén, A., Mathiesen, J. M., and Thomsen, C. (2005) Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol. 97, 202-213.
4. Kew, J. N. C. (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Ther. 104, 233-244.
5. Lindsley, C. W., and Emmitte, K. A. (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr. Opin. Drug Discovery Dev. 12, 446-457.
6. Gasparini, F., Bilbe, G., Gomez-Mancilla, B., and Spooren, W. (2008) mGluR5 antagonists: Discovery, characterization and drug development. Curr. Opin. Drug Discovery Dev. 11, 655-665.
7. Jaeschke, G., Wettstein, J. G., Nordquist, R. E., and Spooren, W. (2008) mGlu5 receptor antagonists and their therapeutic potential. Expert. Opin. Ther. Pat. 18, 123-142.
8. Rodriguez, A. L., and Williams, R. (2007) Recent progress in the development of allosteric modulators of mGluR5. Curr. Opin. Drug Discovery Dev. 10, 715-722.
9. Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, E. C., Hess, S. D., Rao, S. P., Sacaan, A. I., Santori, E. M., Veliocelebi, G., and Kuhn, R. (1999) Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493-1503.
10. Cosford, N. D., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., Rao, S., Washburn, M., and Varney, M. A. (2003) 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46, 204-206.
11. Zhu, C. Z., Wilson, S. G., Mikusa, J. P., Wismer, C. T., Gauvin, D. M., Lynch, J. J., Wade, C. L., Decker, M. W., and Honore, P. (2004) Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur. J. Pharmacol. 506, 107-118.
12. Pietraszek, M., Sukhanov, I., Maciejak, P., Szyndler, J., Gravius, A., Wislowska, A., Plaznik, A., Bespalov, A. Y., and Danysz, W. (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514, 25-34.
13. Busse, C. S., Brodkin, J., Tattersall, D., Anderson, J. J., Warren, N., Tehrani, L., Bristow, L. J., Varney, M. A., and Cosford, N. D. P. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29, 1971-1979.
14. Klodzinska, A., Tatarczynska, E., Chojnacka-Wójcik, E., Nowak, G., Cosford, N. D. P., and Pilc, A. (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 47, 342-350.
15. Spooren, W. P. J. M., Vassout, A., Neijt, H. C., Kuhn, R., Gasparini, F., Roux, S., Porsolt, R. D., and Gentsch, C. (2000) Anxiolyticlike effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295, 1267-1275.
16. Nicolas, L. B., Kolb, Y., and Prinssen, E. P. M. (2006) A combined marble burying-locomoter activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur. J. Pharmacol. 547, 106-115.
17. Jensen, J., Lehmann, A., Uvebrant, A., Carlsson, A., Jerndal, G., Nilsson, K., Frisby, C., Blackshaw, L. A., and Mattsson, J. P. (2005) Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur. J. Pharmacol. 519, 154-157.
18. Frisby, C. L., Mattsson, J. P., Jensen, J. M., Lehmann, A., Dent, J., and Blackshaw, L. A. (2005) Inhibition of transient lower esophageal sphincter relaxtation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 129, 995-1004.
19. Morin, N., Grégoire, L., Gomez-Mancilla, B., Gasparini, F., and Di Paolo, T. (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58, 981-986.
20. de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., and Willemsen, R. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 31, 127-132.
21. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066.
22. Keywood, C., Wakefield, M., and Tack, J. (2009) A proof-ofconcept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58, 1192-1199.
23. Goadsby, P. J. Keywood, C. G. Investigation of the role of mGluR5 inhibition in migraine: A proof of concept study of ADX10059 in acute treatment of migraine. Abstracts of Papers, 61st annual meeting of the American Academy of Neurology, Seattle, WA, April 25-May 2, 2009; American Academy of Neurology: Saint Paul, MN, 2009; P06.006.
24. Berry-Kravis, E. M., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchinson, J., Snape, M., Tranfaglia, M., Nguyen, D. V., and Hagerman, R. (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46, 266-271.
25. Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Gasparini, F., Hariry, S., Johns, D., Gomez-Mancilla, B. Abstracts of Papers, 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, June 7-11, 2009; The Movement Disorder Society: Milwaukee, WI, 2009; LB-05.
26. McGeehan, A. J., and Olive, M. F. (2003) The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 47, 240-242.
27. Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2009) Reinforcing and locomoter stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4, 873-874.
28. Martin-Fardon, R., Baptista, M. A. S., Dayas, C. V., and Weiss, F. (2009) Dissociation of the effects of MTEP [3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine] on conditioned reinstatement and reinforcement: Comparison between cocaine and a conventional reinforcer. J. Pharmacol. Exp. Ther. 329, 1084-1090.
29. Kumaresan, V., Yuan, M., Yee, J., Famous, K. R., Anderson, S.M., Schmidt, H. D., and Pierce, R.C. (2009) Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming-and cue-induced reinstatement of cocaine seeking. Behav. Brain Res. 202, 238-244.
30. Bäckstrom, P., and Hyytiä, P. (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31, 778-786.
31. Iso, Y., Grajkowska, E., Wroblewski, J. T., Davis, J., Goeders, N. E., Johnson, K. M., Sanker, S., Roth, B. L., Tueckmantel, W., and Kozikowski, A. P. (2006) Synthesis and structure-activity relationships of 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J. Med. Chem. 49, 1080-1100.
32. Kenny, P. J., Boutrel, B., Gasparini, F., Koob, G. F., and Markou, A. (2005) Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology 179, 247-254.
33. Tessari, M., Pilla, M., Andreoli, M., Hutcheson, D. M., and Heidbreder, C. A. (2004) Antagonism at metabotropic glutamate 5 receptor inhibits nicotine-and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol. 499, 121-133.
34. Platt, D. M., Rowlett, J. K., and Spealman, R. D. (2008) Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology 200, 167-176.
35. Lee, B., Platt, D. M., Rowlett, J. K., Adewale, A. S., and Spealman, R. D. (2005) Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J. Pharmacol. Exp. Ther. 312, 1232-1240.
36. National Institute on Drug Abuse (2009) Research Report Series, Cocaine: Abuse and Addiction, NIH Publication No. 09-4166, U.S. Department of Health and Human Services, National Institute of Health, Rockville, MD.
37. Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., Martinot, J. L., Reynaud, M., and Lépine, J. P. (2009) New treatments for cocaine dependence: a focused review. Int. J. Neuropsychopharmacology 11, 425-438.
38. Felts, A. S., Saleh, S. A., Le, U., Rodriguez, A. L., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2009) Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg. Med. Chem. Lett. 19, 6623-6626.
39. Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg. Med. Chem. Lett. 19, 6502-6506.
40. Rodriguez, A. L., Williams, R., Zhou, Y., Lindsley, S. R., Le, U., Grier, M. D., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg. Med. Chem. Lett. 19, 3209-3213.
41. Felts, A. S., Lindsley, S. R., Lamb, J. P., Rodriguez, A. L., Menon, U. N., Jadhav, S., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2010) 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in rats. Bioorg. Med. Chem. Lett. 20, 4390-4394.
42. Hamill, T. G., Krause, S., Ryan, C., Bonnefous, C., Govek, S., Seiders, T. J., Cosford, N. D. P., Roppe, J., Kamenecka, T., Patel, S., Gibson, R. E., Sanabria, S., Riffel, K., Eng, W., King, C., Yang, X., Green, M. D., O'Malley, S. S., Hargreaves, R., and Burns, H. D. (2005) Synthesis, characterization, and first successful monkey imaging studies of metabotropic monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 56, 205-216.
43. Kulkarni, S. S., Zou, M.-F., Cao, J., Deschamps, J. R., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2009) Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substitutedarylethynyl) thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. J. Med. Chem. 52, 3563-3575.
44. Milbank, J. B. J., Knauer, C. S., Augelli-Szafran, C. E., Sakkab-Tan, A. T., Lin, K. K., Yamagata, K., Hoffman, J. K., Zhuang, N., Thomas, J., Galatsis, P., Wendt, J. A., Mickelson, J. W., Schwarz, R. D., Kinsora, J. J., Lotarski, S. M., Stakich, K., Gillespie, K. K., Lam, W. W., and Mutlib, A. E. (2007) Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg. Med. Chem. Lett. 17, 4415-4418.
45. Tehrani, L. R., Smith, N. D., Huang, D., Poon, S. F., Roppe, J. R., Seiders, T. J., Chapman, D. F., Chung, J., Cramer, M., and Cosford, N. D. P. (2005) 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists. Bioorg. Med. Chem. Lett. 15, 5061-5064.
46. Shipe, W. D., Wolkenberg, S. E., and Lindsley, C. W. (2005) Accelerating lead development by microwave-enhanced medicinal chemistry. Drug Discovery Today: Technol. 2, 155-161.
47. Lindsley, C. W., Weaver, D., Jones, C., Marnett, L., and Conn, P. J. (2007) Preclinical drug discovery research and training at Vanderbilt. ACS Chem. Biol. 2, 17-20.
48. Galatsis, P., Yamagata, K., Wendt, J. A., Connolly, C. J., Mickelson, J. W., Milbank, J. B. J., Bove, S. E., Knauer, C. S., Brooker, R. M., Augelli-Szafran, C. E., Schwarz, R. D., Kinsora, J. J., and Kilgore, K. S. (2007) Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg. Med. Chem. Lett. 17, 6525-6528.
49. Sharma, S., Rodriguez, A. L., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett. 18, 4098-4101.
50. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 68, 1793-1802.
51. Kulkarni, S. S., and Newman, A. H. (2007) Discovery of heterocyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg. Med. Chem. Lett. 17, 2987-2991.
52. Cosford, N. D. P., Roppe, J., Tehrani, L., Schweiger, E. J., Seiders, T. J., Chaudary, A., Rao, S., and Varney, M. A. (2003) [3H]-Methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 13, 351-354.
53. Peavy, R. D., Sorensen, S. D., and Conn, P. J. (2002) Differential regulation of metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis and extracellular signal-regulated kinase responses by protein kinase C in cultured astrocytes. J. Neurochem. 83, 110-118.
54. Deacon, R. M. J. (2006) Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat. Protoc. 1, 122-124.
55. Njung'e, K., and Handley, S. L. (1991) Effects of 5-HT uptake inhibitors, agonists, and antagonists on the burying of harmless objects by mice: a putative test for anxiolytic agents. Br. J. Pharmacol. 104, 105-112.
56. Broekkamp, C. L., Rijk, H. W., Joly-Gelouin, D., and Lloyd, K. L. (1986) Major tranquilizers can be distinguished from minor tranquilizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur. J. Pharmacol. 126, 223-229.
57. Cloninger, C. R. (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236, 410-416.
58. Zuckerman, M. (1986) Sensation seeking and the endogenous deficit theory of drug abuse. NIDA Res. Monogr. 74, 59-70.
59. Piazza, P. V., Deminiere, J. M., Le Moal, M., and Simon, H. (1989) Factors that predict individual vulnerability to amphetamine selfadministration. Science 245, 1511-1513.
60. Rebec, G. V., Christensen, J. R., Guerra, C., and Bardo, M. T. (1997) Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty. Brain Res. 776, 61-67.
61. Mitchell, M. B., and Gratton, A. (1992) Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. J. Neurosci. 12, 3609-3618.
62. O'Brien, C. P., and Gardner, E. L. (2005) Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol. Ther. 108, 18-58.
63. Olsen, C. M., and Winder, D. G. (2009) Operant sensation seeking engages similar neural substrates to operant drug seeking in C57 mice. Neuropsychopharmacology 34, 1685-1694.
64. Olsen, C. M. Winder, D. G. (2010) Operant sensation seeking in the mouse. J. Visualized Exp. 45, Nov 10, 2010, DOI: 10.3791/2292.
65. Ettenberg, A., Pettit, H. O., Bloom, F. E., and Koob, G. F. (1982) Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology 78, 204-209.
66. Caine, S. B., Thomsen, M., Gabriel, K. I., Berkowitz, J. S., Gold, L. H., Koob, G. F., Tonegawa, S., Zhang, J., and Xu, M. (2007) Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J. Neurosci. 27, 13140-13150.
67. Olsen, C. M., Childs, D. S., Stanwood, G. D., and Winder, D. G. (2010) Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5). PLoS One 5, e15085; DOI: 10.1371/journal. pone.0015085.
68. Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2001) Reinforcing and locomoter stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 9, 873-874.
69. Kalvass, J. C., and Maurer, T. S. (2002) Influence of nonspecific brain and plasma bindin on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 23, 327-338.
70. Olsen, C. M., and Winder, D. G. (2006) A method for singlesession cocaine self-administration in the mouse. Psychopharmacology 187, 13-21.
71. Schramm-Sapyta, N. L., Olsen, C. M., and Winder, D. G. (2006) Cocaine self-administration reduces excitatory responses in mouse nucleus accumbens shell. Neuropsychopharmacology 31, 1444-1451.
72. Grueter, B. A., Gosnell, H. B., Olsen, C. M., Schramm-Sapyta, N. L., Mathews, G. C., Landreth, G. E., and Winder, D. G. (2006) Extracellular-signal regulated kinase 1-dependent subtype 5 metabotropic glutamate receptor induced long-term depression in the bed nucleus of the stria terminalis is disrupted by cocaine administration. J. Neurosci. 26, 3210-3219.